CN104902889A - 用于治疗癌症的β-水解酶抑制剂 - Google Patents

用于治疗癌症的β-水解酶抑制剂 Download PDF

Info

Publication number
CN104902889A
CN104902889A CN201380061004.4A CN201380061004A CN104902889A CN 104902889 A CN104902889 A CN 104902889A CN 201380061004 A CN201380061004 A CN 201380061004A CN 104902889 A CN104902889 A CN 104902889A
Authority
CN
China
Prior art keywords
methyl
furanone
hydroxy
acetoxy
furyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380061004.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·R·万兹
S·德拉蒙特
A·相原
M·J·奥尔森
J-M·托马斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhode Island Hospital
Midwestern University Glendale
Original Assignee
Rhode Island Hospital
Midwestern University Glendale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhode Island Hospital, Midwestern University Glendale filed Critical Rhode Island Hospital
Priority to CN201910949656.0A priority Critical patent/CN110818660B/zh
Publication of CN104902889A publication Critical patent/CN104902889A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/66—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380061004.4A 2012-09-21 2013-09-20 用于治疗癌症的β-水解酶抑制剂 Pending CN104902889A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910949656.0A CN110818660B (zh) 2012-09-21 2013-09-20 用于治疗癌症的β-羟化酶抑制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261704014P 2012-09-21 2012-09-21
US61/704,014 2012-09-21
PCT/US2013/061050 WO2014047519A2 (en) 2012-09-21 2013-09-20 Inhibitors of beta-hydrolase for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910949656.0A Division CN110818660B (zh) 2012-09-21 2013-09-20 用于治疗癌症的β-羟化酶抑制剂

Publications (1)

Publication Number Publication Date
CN104902889A true CN104902889A (zh) 2015-09-09

Family

ID=50342080

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380061004.4A Pending CN104902889A (zh) 2012-09-21 2013-09-20 用于治疗癌症的β-水解酶抑制剂
CN201910949656.0A Expired - Fee Related CN110818660B (zh) 2012-09-21 2013-09-20 用于治疗癌症的β-羟化酶抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910949656.0A Expired - Fee Related CN110818660B (zh) 2012-09-21 2013-09-20 用于治疗癌症的β-羟化酶抑制剂

Country Status (10)

Country Link
US (8) US9771356B2 (https=)
EP (2) EP3345596B1 (https=)
JP (1) JP6469009B2 (https=)
KR (1) KR102137180B1 (https=)
CN (2) CN104902889A (https=)
AU (1) AU2013317791B2 (https=)
CA (1) CA2885762C (https=)
ES (2) ES2660822T3 (https=)
HK (1) HK1208805A1 (https=)
WO (2) WO2014047519A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113924088A (zh) * 2019-02-15 2022-01-11 中西部大学 同位素稳定的特窗酰亚胺化合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2660822T3 (es) 2012-09-21 2018-03-26 Rhode Island Hospital Inhibidores de beta-hidrolasa para tratamiento del cáncer
EP3652542A1 (en) * 2017-07-14 2020-05-20 Protea Biopharma N.V. Methods and means for diagnosing and/or treating a fatiguing illness
WO2019246093A1 (en) * 2018-06-18 2019-12-26 Midwestern University Monoclonal antibodies targeting epitopes of asph
CN109364251A (zh) * 2018-12-06 2019-02-22 苏州大学 Tet蛋白在治疗抑郁症中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD39717A (https=)
DE39717C (de) H. LEHMANN in München, Enhuberstr. 5 part Bleistifthalter
EP0232258B1 (en) 1985-08-02 1990-05-02 Chevron Research And Technology Company Herbicidal 2-(oxa or thia heterocycle)5-amino-3-oxo-4-(substituted-phenyl)-2,3-dihydrofurans
US5314913A (en) * 1992-12-08 1994-05-24 American Home Products Corporation 4- or 5-(substituted sulfonyl)methyl-3(2H)-furanones
JPH09110853A (ja) * 1995-10-12 1997-04-28 Kikkoman Corp ４‐アシルオキシフラノン誘導体又はその塩及びその製造方法
US5698585A (en) 1995-04-13 1997-12-16 Kikkoman Corporation Pharmaceutical preparation for prevention and/or treatment for cataract
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CA2283100A1 (en) 1997-03-14 1998-09-24 Merck Frosst Canada & Co. (methylsulfonyl)phenyl-2-(5h)-furanones with oxygen link as cox-2 inhibitors
US20030031670A1 (en) 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
US6835370B2 (en) 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US20050123545A1 (en) 1999-11-08 2005-06-09 Wands Jack R. Diagnosis and treatment of malignant neoplasms
WO2003018575A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase
US6667330B2 (en) * 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
AU2002950862A0 (en) 2002-08-19 2002-09-12 Biosignal Pty Ltd Furanone derivatives and methods of making same
WO2004035812A2 (en) 2002-10-16 2004-04-29 Isis Innovation Limited Asparaginyl hydroxylases and modulators thereof
US7642361B2 (en) * 2004-01-09 2010-01-05 Eli Lilly And Company Thiophene and furan compounds
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
MX2012014273A (es) * 2010-06-07 2013-03-22 Novomedix Llc Compuestos furanilo y su uso.
ES2660822T3 (es) 2012-09-21 2018-03-26 Rhode Island Hospital Inhibidores de beta-hidrolasa para tratamiento del cáncer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113924088A (zh) * 2019-02-15 2022-01-11 中西部大学 同位素稳定的特窗酰亚胺化合物
US11897857B2 (en) 2019-02-15 2024-02-13 Midwestern University Isotopically-stabilized tetronimide compounds

Also Published As

Publication number Publication date
US20150210677A1 (en) 2015-07-30
WO2014047447A2 (en) 2014-03-27
WO2014047519A3 (en) 2014-05-30
US9771356B2 (en) 2017-09-26
AU2013317791B2 (en) 2018-05-10
EP2897607A2 (en) 2015-07-29
US20190300519A1 (en) 2019-10-03
EP2897607A4 (en) 2016-10-05
US20180009798A1 (en) 2018-01-11
JP6469009B2 (ja) 2019-02-13
CN110818660B (zh) 2023-09-12
KR102137180B1 (ko) 2020-07-24
HK1208805A1 (zh) 2016-03-18
US10787445B2 (en) 2020-09-29
EP3345596B1 (en) 2021-01-20
WO2014047447A3 (en) 2015-07-30
CA2885762A1 (en) 2014-03-27
WO2014047519A2 (en) 2014-03-27
US20220251076A1 (en) 2022-08-11
US20190002453A1 (en) 2019-01-03
AU2013317791A1 (en) 2015-05-07
US20200361925A1 (en) 2020-11-19
ES2865412T3 (es) 2021-10-15
CA2885762C (en) 2022-05-03
CN110818660A (zh) 2020-02-21
KR20150079616A (ko) 2015-07-08
US10106532B2 (en) 2018-10-23
EP3345596A2 (en) 2018-07-11
US10351555B2 (en) 2019-07-16
US10710995B2 (en) 2020-07-14
EP2897607B1 (en) 2017-11-22
US20180237427A1 (en) 2018-08-23
ES2660822T3 (es) 2018-03-26
US20210032233A1 (en) 2021-02-04
JP2015531351A (ja) 2015-11-02
EP3345596A3 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
CN102424681B (zh) 酰基四氢-β-咔啉类化合物及其衍生物、用途及其制备方法
JP2010168387A (ja) マクロファージコロニー刺激因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体
US20220251076A1 (en) Inhibitors of Beta-Hydoxylase for Treatment of Cancer
CN107531683B (zh) Usp7抑制剂化合物及使用方法
TW200815398A (en) A novel indazole derivative having spirocyclic structure in the side chain
BRPI0911679B1 (pt) Composto aciltioureia ou um sal do mesmo, uso do dito composto para tratar câncer, bem como agente farmacêutico, agente antitumoral e composição farmacêutica compreendendo dito composto
JPWO2006104161A1 (ja) ｃ−Ｍｅｔ自己リン酸化阻害作用を有するチエノピリジン誘導体、キノリン誘導体、およびキナゾリン誘導体
BR112016005606B1 (pt) Composto, composição farmacêutica, e usos de um composto
CN110573147A (zh) 用于抑制癌症转移的包含nm23活化剂的药物组合物
JP2023506321A (ja) 心臓病の治療のための心筋細胞増殖活性を有する複素環式誘導体の使用
US11897857B2 (en) Isotopically-stabilized tetronimide compounds
CN118724825A (zh) 一种Mer/HDAC双靶点抑制剂及其在制备抗肿瘤药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1208805

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20150909

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1208805

Country of ref document: HK